QuidelOrtho Corp. Stock
€37.20
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 0.540% | - | - | - | - | - | - |
Boston Scientific | 0.000% | 1.481% | 7.874% | 46.461% | 33.165% | 93.284% | 107.576% |
Waters Corp. | -1.140% | 4.264% | -1.718% | 12.296% | 0.397% | 16.615% | 60.746% |
Illumina Inc. | -2.710% | -9.055% | -11.060% | -42.117% | -18.397% | -66.785% | -63.406% |
Comments
News
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a